Editorial board member Enrico Heffler (Humanitas University, Milan, Italy) considers the increasing evidence that both oral and inhaled corticosteroids can lead, particularly in severe asthmatics, to adverse events that have a significant impact on both patients quality of life and health-related costs.
1. What proportion of patients with asthma are classified as having severe disease? (0:12)
2. What adverse effects are associated with the use of oral and inhaled corticosteroids in patients with severe asthma? (2:19)
1. What are the impact of these adverse effects in terms of patient quality of life and overall expense? (0:12)
2. What effective strategies may be used to minimise the use of corticosteroids in these patients? (2:01)
3. What new treatment strategies are emerging for patients with severe asthma? (3:14)
Speaker disclosure: Enrico Heffler has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In Asthma
Barbara Yawn, CHEST 2022: The role of respiratory specialists in herpes zoster vaccination
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. We caught up with Dr. Barbara Yawn (University of Minnesota, […]
Barbara Yawn, CHEST 2022: Herpes zoster vaccination in people with asthma or chronic obstructive pulmonary disease
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. touchRESPIRATORY were delighted to speak with Dr. Barbara Yawn (University […]
Cristiano Caruso, ERS 2022: 2 Year Findings from the REALITI-A Study of Mepolizumab in Severe Asthma
REALITI-A was an international, prospective, observational cohort study, investigating the real-world corticosteroid-sparing effect of mepolizumab in severe asthma. touchRESPIRATORY caught up with Dr. Cristiano Caruso (Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy) to discuss the aims, design, eligibility criteria and the 2 year findings from REALITI-A. The abstract ‘International, prospective study of mepolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!